The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondro… (NCT02539069) | Clinical Trial Compass
CompletedNot Applicable
The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondrocyte) by Arthroscopy
South Korea10 participantsStarted 2012-10-23
Plain-language summary
A clinical trial to evaluate the long-term efficacy and safety of Chondron (Autologous cultured Chondrocyte) administered through arthroscopy from the drug's 48 weeks efficacy and safety evaluation with 96 weeks follow-up in patients with knee cartilage defects.
Who can participate
Age range15 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients with cartilage defects in their knee (Including Knee OA and Knee TA) \* For a single lesion, less than 15 cm2 cartilage defects; and for multiple lesions, less than 20 cm2
✓. Patients with misalignment of their tibia and femur, unstable ligament in their knee, or bony defects in the lesions of their knee, and/or who had been treated for alignment
✓. Patients which surrounding cartilage are normal
✓. Patients who were 15 years old or older
✓. Patients or their representative (for adults), or patients and their parent/guardian (for minors), who agreed to participate in the study and signed the informed consent form
Exclusion criteria
✕. Patients hypersensitive to bovine protein
✕. Patients hypersensitive to gentamicin antibiotics
✕. Patients with inflammatory arthritis such as rheumatoid arthritis, gout arthritis
✕. Patients with arthritis related to autoimmune disease
✕. Pregnant, breast-feeding patients or those who have a possibility of pregnancy
✕. Patients with accompanying diseases other than articular cartilage defects, including tumors (Exception: if the possibility of Chondron treatment is confirmed with doctor's clinical decision).
. Patients who have a history of receiving radiotherapy, chemotherapy in the last 2 years (Exception: if the possibility of Chondron treatment is confirmed with doctor's clinical decision).
✕. Patients with diabetes (however, patients whose blood sugar test results are normal and do not have any complication of diabetes, when a written opinion that CHONDRON administration is possible is appended by a doctor are excluded)